Rallybio News

JPMorgan Downgrades Rallybio to Neutral From Overweight

JPMorgan Downgrades Rallybio to Neutral From Overweight.

MT NewswiresMay 15 07:31 ET

Express News | Rallybio Corp : JP Morgan Cuts to Neutral From Overweight

ReutersMay 15 00:20 ET

Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Rallybio (RLYB)

TipRanksMay 13 12:10 ET

Express News | Rallybio Files Prospectus Related To Disposition From Time To Time Of Up To 3.6M Shares Of Common Stock By Selling Stockholder

BenzingaMay 10 16:28 ET

Express News | Rallybio Files Prospectus Related to Disposition From Time to Time of up to 3.6 Mln Shares of Common Stock by Selling Stockholder - SEC Filing

ReutersMay 10 16:04 ET

Express News | HC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $9 Price Target

BenzingaMay 10 07:39 ET

Buy Rating Affirmed for Rallybio: Promising FNAIT Drug Candidate and Strong Financials

TipRanksMay 10 06:48 ET

Rallybio's Advancements and Financial Health Prompt a Buy Rating From Analyst Jonathan Wolleben

TipRanksMay 10 00:56 ET

Rallybio | 10-Q: Quarterly report

SEC announcementMay 9 16:18 ET · Announcements

Express News | Rallybio Corp: On Track to Initiate Rlyb212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of Fnait in 2H 2024

ReutersMay 9 08:04 ET

Rallybio: $94.2 M in Cash, Cash Equivalents, and Marketable Securities as of March 31 Provides Runway Into Mid-2026 >RLYB

Rallybio: $94.2 M in Cash, Cash Equivalents, and Marketable Securities as of March 31 Provides Runway Into Mid-2026 >RLYB

Dow JonesMay 9 08:01 ET

Express News | Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

ReutersMay 9 08:00 ET

Rallybio 1Q Loss $19M >RLYB

Rallybio 1Q Loss $19M >RLYB

Dow JonesMay 9 08:00 ET

Express News | Rallybio Q1 Basic EPS USD -0.47

ReutersMay 9 08:00 ET

Press Release: Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates - On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024

Dow JonesMay 9 08:00 ET

Express News | Rallybio Q1 Income From Operations USD -19.787 Million

ReutersMay 9 08:00 ET

Express News | Rallybio Q1 Net Income USD -19.029 Million

ReutersMay 9 08:00 ET

Express News | Rallybio Q1 Operating Expenses USD 19.787 Million

ReutersMay 9 08:00 ET

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today

BusinesswireMay 7 08:00 ET

Express News | JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target

Moomoo 24/7Apr 18 13:18 ET